GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also inv… Read more
GlobeImmune Inc (GBIM) - Total Liabilities
Latest total liabilities as of March 2016: $7.62 Million USD
Based on the latest financial reports, GlobeImmune Inc (GBIM) has total liabilities worth $7.62 Million USD as of March 2016.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GlobeImmune Inc - Total Liabilities Trend (2010–2015)
This chart illustrates how GlobeImmune Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GlobeImmune Inc Competitors by Total Liabilities
The table below lists competitors of GlobeImmune Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GOLDEN RES DEVL
BE:GOR
|
Germany | €721.55 Million |
|
Renewable Innovations Inc.
OTCQB:REII
|
USA | $7.97 Million |
|
Isomet Corp
NASDAQ:IOMT
|
USA | $2.46 Million |
|
Bisichi Mining PLC
LSE:BISI
|
UK | GBX22.12 Million |
Liability Composition Analysis (2010–2015)
This chart breaks down GlobeImmune Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlobeImmune Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlobeImmune Inc (2010–2015)
The table below shows the annual total liabilities of GlobeImmune Inc from 2010 to 2015.
| Year | Total Liabilities | Change |
|---|---|---|
| 2015-12-31 | $8.52 Million | -33.27% |
| 2014-12-31 | $12.76 Million | -93.83% |
| 2013-12-31 | $206.74 Million | +3.18% |
| 2012-12-31 | $200.37 Million | +0.11% |
| 2011-12-31 | $200.14 Million | +10.34% |
| 2010-12-31 | $181.39 Million | -- |